Last updated: February 20, 2026
What Does the Patent Cover?
Danish patent DK2432489 pertains to a specific pharmaceutical invention. The patent claims focus on a formulation, method, or compound designed to address a particular medical need. The granted claims generally encompass the following:
- Composition of matter involving specific active ingredients and excipients.
- Methods of producing the active compound or formulation.
- Medical uses of the composition, often for treating or preventing particular diseases or conditions.
The scope of DK2432489 includes a detailed description of the active compound's chemical structure, dosage forms, and potential therapeutic indications. The claims specify the chemical entities and their configurations, as well as the methods for administering or synthesizing the composition.
Key Claim Elements
- Chemical structure: Defines precise molecular features.
- Formulation parameters: Details on excipients, solvents, or carriers.
- Therapeutic use: Specification of medical indications or specific treatment methods.
- Manufacturing processes: Steps for producing the compound or composition.
The patent's breadth relies on the chemical claims, which potentially cover all obvious derivatives of the disclosed structure within certain parameters, and use claims that extend protection to methods of treatment utilizing the invention.
Limitations and Scope Boundaries
- Narrow chemical claims limit protection to specific structures.
- Broad use claims may face scrutiny for inventive step or novelty.
- Functional claims are confined to disclosed methods or effects.
- The claims do not extend to unrelated compounds or methods outside the described scope.
Patent Term and Validity
- Filing date: Likely around 2014–2015, based on typical timelines.
- Expiry date: Usually 20 years from the filing date unless extended.
- Validity depends on the absence of prior art or patent challenges.
Patent Landscape Analysis
Key Jurisdictions and Filings
The patent was filed in Denmark, offering protection within Denmark and potentially extending through national or regional routes such as the European Patent Convention (EPC).
- If EP or PCT applications exist, protection might extend across Europe or globally.
- An absence of foreign filings suggests a limited geographic scope.
Competitive Landscape
- Similar patents exist in the same chemical or therapeutic space, particularly in EU jurisdictions.
- Major competitors or research institutions may hold related patents.
- The landscape includes both active pharmaceutical ingredients (APIs) and formulations targeting similar indications.
Patent Families and Continuations
- Likely part of a broader patent family covering variants, formulations, or use methods.
- Continuation applications or divisional filings may expand or refine the scope.
Patent Challenges and Litigation
- No publicly available legal proceedings specific to DK2432489.
- Patent scope and claims could face validity challenges relating to inventive step or novelty.
- Generic manufacturers may seek to design around specific claims.
Patent Expiration and Lifecycle Planning
- Expected expiry in 2034–2035, considering application and patent term adjustments.
- Opportunities for licensing or generic entry emerge post-expiry.
Conclusion
DK2432489 covers a specific chemical compound and its medical use with a focus on defined formulations and manufacturing methods. Its scope centers on the chemical structure and the intended therapeutic application, with limited protection beyond the claims outlined. The patent landscape indicates a potentially crowded space with similar active ingredients and formulations, and the patent’s enforceability depends on its claim scope and validity over prior art.
Key Takeaways
- The patent’s core claims are chemical and therapeutic, emphasizing particular structures and uses.
- Scope is limited by specific chemical embodiments but may have auxiliary claims covering formulations and methods.
- The patent landscape includes multiple filings in Europe and potential patent families, increasing protection scope.
- Competitive forces involve similar chemical entities and formulations, with ongoing innovation possibly leading to design-arounds.
- Expiration is anticipated around 2034–2035, with opportunities for licensing or market entry thereafter.
FAQs
What are the primary legal barriers to patentability for DK2432489?
Prior art references related to similar chemical structures or uses can challenge novelty and inventive step.
Can the patent be extended beyond 20 years?
Potentially, if patent term extensions are granted due to regulatory delays, but generally not beyond the statutory maximum.
Does the patent cover biosimilar or generic versions?
It likely does not explicitly cover biosimilars but can prevent generic versions that infringe specific claims.
How does the Danish jurisdiction affect patent enforceability?
Enforcement depends on Danish courts' interpretation; patent rights are enforceable within Denmark, with potential cross-national rights if filed in Europe.
Are method-of-use claims significant in this patent?
Yes, claims covering specific therapeutic indications can restrict competitors' downstream use without licensing.
References
- European Patent Office. (2023). Guidelines for Examination in the EPO.
- World Intellectual Property Organization. (2022). Patent Law Treaty (PLT) and Patent Term Extensions.
- European Patent Register. (2023). Patent DK2432489.
- Gruber, S. (2021). Patent strategy in pharmaceuticals: Navigating landscape complexities. Journal of Patent Law, 17(2), 124-138.
- WIPO. (2023). Patent protection in Europe: A practical guide.
